Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||DS-1205b + Erlotinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|DS-1205b||AXL Inhibitor 29||DS-1205b inhibits AXL, which potentially results in decreased cell migration, and reduced tumor growth (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #395P, PMID: 31497246).|
|Erlotinib||Tarceva||CP358774||EGFR Inhibitor (Pan) 54 EGFR Inhibitor 1st gen 3||Tarceva (erlotinib) is a first-generation EGFR inhibitor, which is FDA approved for non-small cell lung carcinoma patients with EGFR exon 19 deletions and/or EGFR L858R and in combination with gemcitabine for patients with advanced pancreatic cancer (FDA.gov; PMID: 25302162).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|